Floatz logo

Nivolumab

Oral Cavity Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Oral Cavity Carcinoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Vrp-Encapsulated Sarna Encoding Il-12
VLP Therapeutics
Phase 1CC
Pembrolizumab
VLP Therapeutics
Phase 1CC
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER
Masonic Cancer Center, University of Minnesota
N/AD

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →